The US Food and Drug Administration (FDA) has approved an investigational new drug (IND) application from Aclaris ...

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced that the U.S. Food and Drug Administration (FDA) has approved its ...

Aclaris Therapeutics (NASDAQ:ACRS) said on Tuesday that the U.S. FDA has cleared its investigational new drug application to ...

Ebdarokimab is the company's first Class 1 new drug approved for autoimmune diseases and the second non-oncology new drug to receive marketing approval, following ebronucimab (PCSK9). This approval ...

Cancer Monoclonal Antibody Market Cancer rates continue to rise, especially in aging populations and areas affected by pollution and lifest ...

Aclaris Therapeutics (ACRS) announced that the FDA has cleared its Investigational New Drug – IND – application for a Phase 1a/1b clinical trial of ATI-052, a potential best-in-class bispecific ...

Type II: GA101 is a third-generation, fully humanized, glycoengineered Fc region resulting in a much higher antibody-dependent cellular cytotoxicity level. Anti-CD22 Monoclonal Antibodies ...

an anti-CTLA-4 monoclonal antibody; IBI-323, a novel LAG3/PD-L1 bispecific antibody; IBI-363, a potential PD-1/IL-2 bispecific antibody fusion protein; IBI-343, a recombinant anti-CLDN18.2 ...

an anti-CTLA-4 monoclonal antibody; IBI-323, a novel LAG3/PD-L1 bispecific antibody; IBI-363, a potential PD-1/IL-2 bispecific antibody fusion protein; IBI-343, a recombinant anti-CLDN18.2 ...